TY - JOUR
T1 - Treatment of pulmonary neuroendocrine tumours
T2 - State of the art and future developments
AU - Gridelli, Cesare
AU - Rossi, Antonio
AU - Airoma, Giuseppe
AU - Bianco, Roberto
AU - Costanzo, Raffaele
AU - Daniele, Bruno
AU - Chiara, Giovanni De
AU - Grimaldi, Giuseppe
AU - Irtelli, Luciana
AU - Maione, Paolo
AU - Morabito, Alessandro
AU - Piantedosi, Franco Vito
AU - Riccardi, Ferdinando
PY - 2013/8
Y1 - 2013/8
N2 - The current classification of pulmonary neuroendocrine tumours includes four subtypes: low-grade typical carcinoid tumour (TC), intermediate-grade atypical carcinoid tumour (AC), and two high-grade malignancies: large cell neuroendocrine carcinoma and small cell lung cancer (SCLC).Unfortunately, with the exclusion of SCLC, no large phase II and III trials for pulmonary neuroendocrine tumours have been published. Thus, several treatment approaches are available for their treatment but none of them has been validated in appropriately designed and adequately sized clinical trials. The main problem of the published studies is that they include neuroendocrine tumours from various sites of origin with different clinical behaviour. It is important that future studies consider these tumours separately. In this regard, increased awareness and referral of these patients to tertiary centres, in which a multidisciplinary management is available, may be of value.The aim of this review is to evaluate the state of the art and discuss future developments in the management of pulmonary neuroendocrine tumours excluding SCLC which we consider should be addressed in a different issue.
AB - The current classification of pulmonary neuroendocrine tumours includes four subtypes: low-grade typical carcinoid tumour (TC), intermediate-grade atypical carcinoid tumour (AC), and two high-grade malignancies: large cell neuroendocrine carcinoma and small cell lung cancer (SCLC).Unfortunately, with the exclusion of SCLC, no large phase II and III trials for pulmonary neuroendocrine tumours have been published. Thus, several treatment approaches are available for their treatment but none of them has been validated in appropriately designed and adequately sized clinical trials. The main problem of the published studies is that they include neuroendocrine tumours from various sites of origin with different clinical behaviour. It is important that future studies consider these tumours separately. In this regard, increased awareness and referral of these patients to tertiary centres, in which a multidisciplinary management is available, may be of value.The aim of this review is to evaluate the state of the art and discuss future developments in the management of pulmonary neuroendocrine tumours excluding SCLC which we consider should be addressed in a different issue.
KW - Carcinoids
KW - Large cell neuroendocrine carcinoma
KW - Lung cancer
KW - Pulmonary neuroendocrine tumours
KW - Somatostatin analogues therapy
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84876991156&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876991156&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2012.06.012
DO - 10.1016/j.ctrv.2012.06.012
M3 - Article
C2 - 22818212
AN - SCOPUS:84876991156
VL - 39
SP - 466
EP - 472
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
SN - 0305-7372
IS - 5
ER -